

Docket No.: A0345.0012
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Hamed Aissaoui et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: QUINOXALINONE-3-ONE
DERIVATIVES AS OREXIN RECEPTOR
ANTAGONISTS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.97, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Timing of Filing of the Information Disclosure Statement:

- ☒ This IDS is being filed before the First Office Action¹.
- ☐ This IDS is being filed after the issuance of the First Office Action but before the issuance of a Final Office Action².

¹ The IDS should, where possible, include a certification under 37 C.F.R. §1.97(e).

² The IDS *must* include *either* a certification under 37 C.F.R. §1.97(e) *or* the fee set forth in 37 C.F.R. §1.17(p).

- ☐ This IDS is being filed after the issuance of a Final Office Action or Notice of Allowance but before the payment of the Final Fee³.

Certifications:

If checked, the undersigned makes the following statement(s):

- ☐ Statement under 37 CFR § 1.97(e):

Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement; or

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

- ☐ Statement Under 37 C.F.R. § 1.704(d):

Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application less than thirty days prior to the filing of this information disclosure statement.

Fee Required by 37 C.F.R. § 1.97(c)(2) or 1.97(d)(2):

³ The IDS *must* include *both* a certification under 37 C.F.R. §1.97(e) *and* the fee set forth in 37 C.F.R. §1.17(p).

☐ If checked, the fee of \$180.00 set forth in 37 C.F.R. §1.17(p) is attached.

Copies of Information:

In accordance with 37 C.F.R. §1.98(a), the following are enclosed:

- ☒ A legible copy⁴ of each document (or relevant portion thereof) is cited in the attached PTO/SB/08.
- ☒ With respect to any information which is not in English, a concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56(c) most knowledgeable about the content of the information, is attached. This concise explanation is provided by way of:
- ☐ A translation of the relevant portions of the non-English language information⁵;
 - ☐ A statement explaining the relevant portions of the non-English language information;
 - ☐ A copy [and, where not in the English language, a translation] of at least the relevant portion(s)⁶ of the communication from a foreign patent office in a counterpart foreign application in which the information was cited; or

⁴ A legible copy of the document is not required if (1) the information was previously cited by, or submitted to, the Office and considered by the Office in a prior U.S. application to which this application claims priority, provided that the prior application is properly identified in this IDS, and (2) the IDS submitted in the earlier application complies with 37 C.F.R. § 1.98(a) – (c). This exception does not apply to information cited in an International Application.

⁵ 37 C.F.R. §1.98(a)(3)(ii) *requires* that an English language translation be provided when a translation of the document, or portion thereof, “is within the possession, custody or control of, or is readily available to any individual designated in 37 C.F.R. § 1.56(c).”

⁶ The relevant portion is that portion which indicates the degree of relevance found by the foreign patent office. This may be an explanation of which portion of the of the reference is particularly relevant, to which claims it applies, or merely an “X”, “Y”, or “A” indication on a search report. MPEP §609 III A(3).

☒ This information is contained in the specification of the present application.

☐ In accordance with 37 C.F.R. 1.98(d), copies of the cited documents are not enclosed as they were provided in application Serial No. _____, filed _____, which the present application relies upon for an earlier effective filing date under 35 U.S.C. 120.

Materiality:

Whether or not the information and references disclosed in this Information Disclosure Statement is "material" pursuant to 37 CFR 1.56, this submission is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

In the event the actual fee is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 50-2215.

Dated: October 27, 2005

Respectfully submitted,

By 
Charles E. Miller
Registration No.: 27,576
DICKSTEIN SHAPIRO MORIN &
OSHINSKY LLP
1177 Avenue of the Americas, 41st Floor
New York, NY 10036-2714
(212) 835-1400

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Hamed Aissaoui
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	A0345.0012

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-03/051873-A1	06-26-2003	SMITHKLINE BEECHAM PLC		
	BB	WO-03/032991-A1	04-24-2003	SMITHKLINE BEECHAM PLC		
	BC	WO-03/041711-A1	05-22-2003	SMITHKLINE BEECHAM PLC		
	BD	WO-03/037847-A1	05-08-2003	SMITHKLINE BEECHAM PLC		
	BE	WO-03/051872-A1	06-26-2003	SMITHKLINE BEECHAM PLC		
	BF	WO-01/068609-A1	09-20-2001	ACTELION PHARMACEUTICALS LTD.	Cited in the International Search Report	
	BG	WO-02/051838-A1	07-04-2002	ACTELION PHARMACEUTICALS LTD		
	BH	WO-99/58533	11-18-1999	SMITHKLINE BEECHAM PLC		
	BI	WO-99/09024	02-25-1999	SMITHKLINE BEECHAM PLC		
	BJ	WO-00/47576	08-17-2000	SMITHKLINE BEECHAM PLC		
	BK	WO-00/47577-A1	08-17-2000	SMITHKLINE BEECHAM PLC	Cited in the International Search Report.	
	BL	WO-00/47580-A1	08-17-2000	SMITHKLINE BEECHAM PLC	Cited in the International Search Report.	
	BM	WO-01/96302-A1	12-20-2001	SMITHKLINE BEECHAM P.L.C.		
	BN	WO-02/44172-A1	06-06-2002	SMITHKLINE BEECHAM P.L.C.		
	BO	WO-02/090355-A1	11-14-2002	SMITHKLINE BEECHAM PLC		
	BP	WO-02/089800-A2	11-14-2002	SMITHKLINE BEECHAM PLC		
	BQ	WO-03/002559-A2	01-09-2003	SMITHKLINE BEECHAM PLC		
	BR	WO-03/002561-A1	01-09-2003	SMITHKLINE BEECHAM PLC		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Hamed Aissaoui
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	A0345.0012

BS	WO-2004/004733-A1	01-15-2004	ACTELION PHARMACEUTICALS LTD.	Cited in the International Search Report
----	-------------------	------------	----------------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	CA	H. Abdel-Ghany, et al.; "A Novel Syntheses of Pyrano(2,3-c)(1,5)Benzodiazepines"; Synthetic Communications; Vol. 20(6); 1990; pp. 893-900		
	CB	Richard M. Chemelli, et al.; "Narcolepsy in orexin Knockout Mice: Molecular Genetics of Sleep Regulation"; Cell; Vol. 98; August 20, 1999; pp. 437-451		
	CC	A.M. Farghaly, et al.; "Synthesis of 3-Aryl-2-Substituted-4(3H)-Quinazolines as Potential Antimicrobial Agents"; Il Farmaco; Vol. 45(4); 1990; pp. 431-438		
	CD	Diana G. Bekerman, et al.; "Comparative Kinetic Studies on the Synthesis of Quinoxalinone Derivatives and Pyrido[2,3-b]pyrazinone Derivatives by the Hinsberg Reaction"; J. Heterocyclic Chem.; Vol. 29; Jan-Feb 1992; pp. 129-133		
	CE	M. F. Ismail, et al.; "Reaction of 6,8-Dibromo-2-methyl-3, 1-benzoxazin-4(H)-one with Some Nucleophilic Reagents: Synthesis of Quinazoline, Tetrazole & Benzimidazole Derivatives"; Indian Journal of Chemistry; Vol. 20B; May 1981; pp. 394-397		
	CF	Jozsef Kokosi, et al.; "Nitrogen Bridgehead Compounds Part 90. An Efficient Versatile Synthesis of 1-Methyl-2-Substituted 1,2,3,4-Tetrahydro-6H-Pyrazino[2,1-b]Quinazoline-3,6-Diones"; Heterocycles; Vol. 48(9); 1998; pp. 1851-1866		
	CG	David S. Lawrence, et al.; "Structure-Activity Studies of Substituted Quinoxalinones as Multiple-Drug-Resistance Antagonists"; J. Med. Chem.; Vol. 44; 2001; pp. 594-601		
	CH	"Aliphatic Nucleophilic Substitution"; pp. 418		
	CI	Hiroyuki Obase, et al.; "Synthesis of (1-Substituted Piperidin-4-yl)-1H-benzimidazoles and (1-Substituted Piperidin-4-yl)-3,4-dihydroquinazolines as Possible Antihypertensive Agents"; J. Heterocyclic Chem.; Vol. 20; May-June 1983; pp. 565-573		
	CJ	Takeshi Sakurai, et al.; "Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding Behavior"; Cell.; Vol. 92; February 20, 1998; pp. 573-585		
	CK	Karnail S. Atwal, et al.; "A Facile Synthesis of Cyanoguanidines From Thioureas"; Tetrahedron Letters; Vol. 30(52); 1989; pp. 7313-7316		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--